Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
NOVOCURE LIMITED |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 12.5 USD | -2.95% | 0.00% | -82.96% | |
| Nov. 29 | Transcript : NovoCure Limited Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 03:30 PM | CI |
| Nov. 28 | Sector Update: Health Care Stocks Ease Tuesday Afternoon | MT |
Valuation
| Fiscal Period : December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3 114 | 8 340 | 17 615 | 7 795 | 7 698 | 1 336 | - | - |
| Enterprise Value (EV) 1 | 3 123 | 8 312 | 17 810 | 8 148 | 8 148 | 1 786 | 1 269 | 1 221 |
| P/E ratio | -48,5x | -1 204x | 865x | -134x | -83,4x | -6,17x | -6,40x | -5,82x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 12,6x | 23,7x | 35,6x | 14,6x | 14,3x | 2,65x | 2,49x | 2,35x |
| EV / Revenue | 12,6x | 23,7x | 36,0x | 15,2x | 15,1x | 3,54x | 2,37x | 2,15x |
| EV / EBITDA | - | 1 102x | 450x | -239x | -103x | -7,68x | -5,19x | -4,88x |
| EV / FCF | -364x | 515x | 212x | 139x | 864x | -15,0x | -8,84x | - |
| FCF Yield | -0,27% | 0,19% | 0,47% | 0,72% | 0,12% | -6,66% | -11,3% | - |
| Price to Book | 27,4x | 38,5x | 37,2x | 19,0x | - | - | - | - |
| Nbr of stocks (in thousands) | 93 014 | 98 969 | 101 797 | 103 819 | 104 950 | 106 861 | - | - |
| Reference price 2 | 33,5 | 84,3 | 173 | 75,1 | 73,4 | 12,5 | 12,5 | 12,5 |
| Announcement Date | 2/28/19 | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period : December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 248 | 351 | 494 | 535 | 538 | 505 | 536 | 568 |
| EBITDA 1 | - | 7,55 | 39,6 | -34,1 | -78,9 | -232 | -245 | -250 |
| EBIT 1 | -33,7 | -0,91 | 30,4 | -44,3 | -89,5 | -246 | -265 | -293 |
| Operating Margin | -13,6% | -0,26% | 6,15% | -8,29% | -16,6% | -48,7% | -49,5% | -51,6% |
| Earnings before Tax (EBT) 1 | -45,9 | -8,82 | 18,1 | -52,1 | -81,8 | -208 | -227 | -258 |
| Net income 1 | -63,6 | -7,23 | 19,8 | -58,4 | -92,5 | -217 | -226 | -264 |
| Net margin | -25,6% | -2,06% | 4,01% | -10,9% | -17,2% | -42,9% | -42,3% | -46,6% |
| EPS 2 | -0,69 | -0,07 | 0,20 | -0,56 | -0,88 | -2,03 | -1,95 | -2,15 |
| Free Cash Flow 1 | -8,58 | 16,1 | 84,2 | 58,6 | 9,43 | -119 | -144 | - |
| FCF margin | -3,46% | 4,59% | 17,0% | 11,0% | 1,75% | -23,6% | -26,8% | - |
| FCF Conversion (EBITDA) | - | 214% | 213% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | 425% | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/19 | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period : December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 134 | 134 | 133 | 138 | 141 | 131 | 128 | 122 | 126 | 127 | 129 | 131 | 135 | 137 | 140 |
| EBITDA 1 | -9,82 | -5,82 | -20,7 | 1,80 | -18,5 | -22,0 | -40,3 | -57,5 | -59,9 | -55,4 | -58,3 | -59,0 | -58,4 | -56,1 | -55,5 |
| EBIT 1 | -12,3 | -8,55 | -23,4 | -0,81 | -21,1 | -24,6 | -43,0 | -60,2 | -62,7 | -58,2 | -64,8 | -59,4 | -61,2 | -61,7 | -62,3 |
| Operating Margin | -9,21% | -6,40% | -17,6% | -0,59% | -15,0% | -18,8% | -33,5% | -49,3% | -49,7% | -45,7% | -50,1% | -45,2% | -45,4% | -44,9% | -44,5% |
| Earnings before Tax (EBT) 1 | -13,2 | -10,5 | -25,6 | -2,52 | -23,4 | -23,4 | -32,6 | -51,1 | -53,9 | -48,2 | -54,8 | -49,4 | -51,2 | -51,7 | -52,3 |
| Net income 1 | -14,6 | -13,1 | -26,5 | -4,65 | -24,0 | -26,6 | -37,3 | -53,1 | -57,4 | -49,5 | -56,7 | -50,7 | -51,3 | -50,9 | -50,5 |
| Net margin | -11,0% | -9,82% | -19,9% | -3,38% | -17,0% | -20,3% | -29,0% | -43,4% | -45,6% | -38,9% | -43,9% | -38,6% | -38,1% | -37,1% | -36,1% |
| EPS 2 | -0,14 | -0,13 | -0,25 | -0,04 | -0,23 | -0,25 | -0,36 | -0,50 | -0,54 | -0,46 | -0,52 | -0,47 | -0,48 | -0,47 | -0,49 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 7/29/21 | 10/28/21 | 2/24/22 | 4/28/22 | 7/28/22 | 10/27/22 | 2/23/23 | 5/4/23 | 7/27/23 | 10/26/23 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period : December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 8,65 | - | 195 | 353 | 450 | 450 | - | - |
| Net Cash position 1 | - | 27,9 | - | - | - | - | 66,7 | 115 |
| Leverage (Debt/EBITDA) | - | - | 4,94x | -10,4x | -5,71x | -1,94x | - | - |
| Free Cash Flow 1 | -8,58 | 16,1 | 84,2 | 58,6 | 9,43 | -119 | -144 | - |
| ROE (net income / shareholders' equity) | -56,3% | -4,38% | 5,71% | -13,2% | -21,7% | -56,5% | -64,5% | -78,0% |
| Shareholders' equity 1 | 113 | 165 | 347 | 444 | 426 | 384 | 351 | 339 |
| ROA (Net income/ Total Assets) | -21,0% | -1,77% | 2,59% | -5,33% | -7,94% | -19,5% | -24,4% | -37,6% |
| Assets 1 | 303 | 410 | 766 | 1 096 | 1 166 | 1 114 | 928 | 704 |
| Book Value Per Share | 1,22 | 2,19 | 4,66 | 3,95 | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 6,71 | 10,5 | 15,0 | 24,2 | 21,4 | 16,0 | 24,0 | 32,0 |
| Capex / Sales | 2,71% | 2,98% | 3,03% | 4,52% | 3,97% | 3,17% | 4,48% | 5,64% |
| Announcement Date | 2/28/19 | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
12.5USD
Average target price
26.14USD
Spread / Average Target
+109.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -82.96% | 1 336 M $ | |
| +0.71% | 8 647 M $ | |
| -15.28% | 6 427 M $ | |
| +7.26% | 6 029 M $ | |
| -29.46% | 5 515 M $ | |
| +29.85% | 5 276 M $ | |
| +4.74% | 4 610 M $ | |
| -0.80% | 3 631 M $ | |
| +24.56% | 3 551 M $ | |
| -27.31% | 2 423 M $ |
- Stock
- Equities
- Stock NovoCure Limited - Nasdaq
- Financials NovoCure Limited
